TY - JOUR
T1 - Nanoparticles for nucleic acid delivery
T2 - Applications in cancer immunotherapy
AU - Mukalel, Alvin J.
AU - Riley, Rachel S.
AU - Zhang, Rui
AU - Mitchell, Michael J.
N1 - Funding Information:
The authors acknowledge support from a Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI) , a US National Institutes of Health (NIH) Director's New Innovator Award ( DP2 TR002776 ), a grant from the American Cancer Society ( 129784-IRG-16-188-38-IRG ), an Abramson Cancer Center (ACC)-School of Engineering and Applied Sciences (SEAS) Discovery Grant ( P30 CA016520 ), and a 2018 AACR-Bayer Innovation and Discovery Grant, Grant Number 18-80-44-MITC (to M.J.M.). R.S.R. is supported by an NIH T32 multidisciplinary training grant ( T32 HL007954 ). A.J.M. is supported by an NSF Graduate Research Fellowship .
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/8/28
Y1 - 2019/8/28
N2 - Immunotherapy has recently emerged as a powerful tool for cancer treatment. Early clinical successes from cancer immunotherapy have led to a growing list of FDA approvals, and many new therapies are in clinical and preclinical development. Nucleic acid therapeutics, including DNA, mRNA, and genome editing systems, hold significant potential as a form of immunotherapy due to its robust use in cancer vaccination, adoptive T-cell therapy, and gene regulation. However, these therapeutics must overcome numerous delivery obstacles to be successful, including rapid in vivo degradation, poor uptake into target cells, required nuclear entry, and potential in vivo toxicity in healthy cells and tissues. Nanoparticle delivery systems have been engineered to overcome several of these barriers as a means to safely and effectively deliver nucleic acid therapeutics to immune cells. In this Review, we discuss the applications of nucleic acid therapeutics in cancer immunotherapy, and we detail how nanoparticle platforms have been designed to deliver mRNA, DNA, and genome editing systems to enhance the potency and safety of these therapeutics.
AB - Immunotherapy has recently emerged as a powerful tool for cancer treatment. Early clinical successes from cancer immunotherapy have led to a growing list of FDA approvals, and many new therapies are in clinical and preclinical development. Nucleic acid therapeutics, including DNA, mRNA, and genome editing systems, hold significant potential as a form of immunotherapy due to its robust use in cancer vaccination, adoptive T-cell therapy, and gene regulation. However, these therapeutics must overcome numerous delivery obstacles to be successful, including rapid in vivo degradation, poor uptake into target cells, required nuclear entry, and potential in vivo toxicity in healthy cells and tissues. Nanoparticle delivery systems have been engineered to overcome several of these barriers as a means to safely and effectively deliver nucleic acid therapeutics to immune cells. In this Review, we discuss the applications of nucleic acid therapeutics in cancer immunotherapy, and we detail how nanoparticle platforms have been designed to deliver mRNA, DNA, and genome editing systems to enhance the potency and safety of these therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85066505335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066505335&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2019.04.040
DO - 10.1016/j.canlet.2019.04.040
M3 - Review article
C2 - 31100411
AN - SCOPUS:85066505335
SN - 0304-3835
VL - 458
SP - 102
EP - 112
JO - Cancer Letters
JF - Cancer Letters
ER -